Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
PLoS One. 2012;7(2):e30659. doi: 10.1371/journal.pone.0030659. Epub 2012 Feb 9.
Interleukin-6 (IL-6) contributes to numerous inflammatory, metabolic, and physiologic pathways of disease. We evaluated four IL-6 immunoassays in order to identify a reliable assay for studies of metabolic and physical function. Serial plasma samples from intravenous glucose tolerance tests (IVGTTs), with expected rises in IL-6 concentrations, were used to test the face validity of the various assays.
IVGTTs, administered to 14 subjects, were performed with a single infusion of glucose (0.3 g/kg body mass) at time zero, a single infusion of insulin (0.025 U/kg body mass) at 20 minutes, and frequent blood collection from time zero to 180 minutes for subsequent Il-6 measurement. The performance metrics of four IL-6 detection methods were compared: Meso Scale Discovery immunoassay (MSD), an Invitrogen Luminex bead-based multiplex panel (LX), an Invitrogen Ultrasensitive Luminex bead-based singleplex assay (ULX), and R&D High Sensitivity ELISA (R&D). IL-6 concentrations measured with MSD, R&D and ULX correlated with each other (Pearson Correlation Coefficients r = 0.47-0.94, p<0.0001) but only ULX correlated (r = 0.31, p = 0.0027) with Invitrogen Luminex. MSD, R&D, and ULX, but not LX, detected increases in IL-6 in response to glucose. All plasma samples were measurable by MSD, while 35%, 1%, and 4.3% of samples were out of range when measured by LX, ULX, and R&D, respectively. Based on representative data from the MSD assay, baseline plasma IL-6 (0.90 ± 0.48 pg/mL) increased significantly as expected by 90 minutes (1.29 ± 0.59 pg/mL, p = 0.049), and continued rising through 3 hours (4.25 ± 3.67 pg/mL, p = 0.0048).
This study established the face validity of IL-6 measurement by MSD, R&D, and ULX but not LX, and the superiority of MSD with respect to dynamic range. Plasma IL-6 concentrations increase in response to glucose and insulin, consistent with both an early glucose-dependent response (detectable at 1-2 hours) and a late insulin-dependent response (detectable after 2 hours).
白细胞介素 6(IL-6)参与多种炎症、代谢和生理疾病途径。我们评估了四种 IL-6 免疫分析方法,以确定用于研究代谢和身体功能的可靠方法。预期 IL-6 浓度升高的静脉内葡萄糖耐量试验(IVGTT)的连续血浆样本用于测试各种分析的表面有效性。
对 14 名受试者进行 IVGTT,在 0 分钟时给予 0.3g/kg 体重的葡萄糖单次输注,在 20 分钟时给予 0.025U/kg 体重的胰岛素单次输注,并在 0 分钟至 180 分钟内频繁采血以随后测量 Il-6。比较了四种 IL-6 检测方法的性能指标:Meso Scale Discovery 免疫分析(MSD)、Invitrogen Luminex 珠基多重面板(LX)、Invitrogen Ultrasensitive Luminex 珠基单plex 测定(ULX)和 R&D 高灵敏度 ELISA(R&D)。MSD、R&D 和 ULX 测量的 IL-6 浓度相互相关(Pearson 相关系数 r=0.47-0.94,p<0.0001),但只有 ULX 与 Invitrogen Luminex 相关(r=0.31,p=0.0027)。MSD、R&D 和 ULX 检测到葡萄糖反应的 IL-6 增加,但 LX 未检测到。所有血浆样本均可通过 MSD 测量,而 LX、ULX 和 R&D 分别有 35%、1%和 4.3%的样本超出测量范围。基于 MSD 分析的代表性数据,基线血浆 IL-6(0.90±0.48pg/mL)在 90 分钟时按预期显着增加(1.29±0.59pg/mL,p=0.049),并在 3 小时时继续升高(4.25±3.67pg/mL,p=0.0048)。
本研究通过 MSD、R&D 和 ULX 但不是 LX 确立了 IL-6 测量的表面有效性,并且 MSD 在动态范围方面具有优势。血浆 IL-6 浓度随葡萄糖和胰岛素而增加,与早期葡萄糖依赖性反应(可在 1-2 小时检测到)和晚期胰岛素依赖性反应(可在 2 小时后检测到)一致。